Trial Profile

ADEPT: Phase II neo-adjuvant study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Degarelix (Primary) ; Erdafitinib (Primary)
Indications Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ADEPT

Most Recent Events

11 Feb 2021 Planned End Date changed from 30 Sep 2019 to 12 Mar 2021.
11 Feb 2021 Status changed from recruiting to discontinued.Reason: The first phase of recruitment is complete. The end points from phase one were not met in order to continue to the second phase of recruitment.
19 Jul 2019 Planned End Date changed from 1 Jan 2020 to 30 Sep 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com